Purpose: There are several mechanisms involved in the process of cervical epithelial carcinogenesis. We all know that Type 2 diabetes is connected with higher cancer mortality, including cervical cancers. Nevertheless, there is no sufficient evidence linking higher blood glucose to greater cervical epithelial morbidity. The study accordingly aims at exploring whether higher serum glucose level induces pathogenesis of cervical epithelial cells.
Methods: The research is a retrograde cohort study based on a single hospital database containing all the Pap smear and cervical biopsy data of 3,937 subjects collected during the period from January, 2011 to December, 2017. Every subject received at least two pap-smear exams during the study period, and those with abnormality confirmed in one pap smear were required to have cervical biopsy. All subjects were stratified by fasting serum glucose level into three groups (fasting serum glucose < 100 mg/dL, 100-125 mg/dL, and ≥ 126 mg/dL). Logistic regression model was used for analysis to adjust multiple risk factors, and p value was double-sided.
Results: The abnormality rate read 12.9% in the first pap-smear test increased to 16.2% in the second test. With multiple risk factors adjusted, compared with those with normal fasting serum glucose, subjects with higher fasting serum glucose showed not only a higher rate of exacerbated pap smears and cervical biopsy outcomes (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.00-2.16 in glucose level 100-125 mg/dL , and OR 1.85, 95% CI 0.99-3.45 in glucose level ≥ 126 mg/dL) but also a lower rate of regressing from cervical pre-cancer lesions (OR 0.29, 95% CI 0.13-0.64 in glucose level 100-125 mg/dL, and OR 0.08, 95% CI 0.02-0.28 in glucose level ≥ 126 mg/dL).
Conclusion: High fasting serum glucose may lead to worsening of cervical epithelial pre-cancer lesions and prevent cervical pre-cancer lesions from regressing.